Rhumbline Advisers Acquires 40,813 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Rhumbline Advisers boosted its holdings in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 44.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 132,825 shares of the company’s stock after purchasing an additional 40,813 shares during the period. Rhumbline Advisers owned about 0.19% of Ventyx Biosciences worth $291,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of VTYX. Catalina Capital Group LLC purchased a new position in shares of Ventyx Biosciences during the fourth quarter valued at approximately $25,000. Intech Investment Management LLC bought a new stake in Ventyx Biosciences in the third quarter valued at $42,000. Barclays PLC increased its position in Ventyx Biosciences by 273.1% during the 3rd quarter. Barclays PLC now owns 80,295 shares of the company’s stock valued at $175,000 after purchasing an additional 58,776 shares during the period. LMR Partners LLP bought a new position in Ventyx Biosciences in the 3rd quarter worth $218,000. Finally, XTX Topco Ltd purchased a new stake in shares of Ventyx Biosciences in the 3rd quarter worth about $246,000. Institutional investors own 97.88% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Ventyx Biosciences in a research note on Tuesday, January 14th.

Ventyx Biosciences Stock Down 3.9 %

VTYX opened at $1.49 on Monday. Ventyx Biosciences, Inc. has a 52 week low of $1.37 and a 52 week high of $11.48. The stock has a market cap of $105.98 million, a PE ratio of -0.63 and a beta of 0.58. The business has a 50 day moving average of $1.89 and a 200-day moving average of $2.13.

Ventyx Biosciences (NASDAQ:VTYX) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.13. Equities analysts anticipate that Ventyx Biosciences, Inc. will post -2.09 EPS for the current year.

Insider Activity at Ventyx Biosciences

In related news, Director Sheila Gujrathi bought 130,000 shares of the business’s stock in a transaction dated Monday, December 23rd. The shares were purchased at an average cost of $2.31 per share, with a total value of $300,300.00. Following the completion of the purchase, the director now owns 130,000 shares in the company, valued at approximately $300,300. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider John Nuss sold 13,161 shares of the firm’s stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $2.26, for a total value of $29,743.86. Following the transaction, the insider now owns 485,701 shares of the company’s stock, valued at $1,097,684.26. The trade was a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 18.18% of the stock is currently owned by corporate insiders.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.